Neogenomics Inc.
NEO
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
158.4% downsideOvervalued by 158.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $392.88 Million |
|---|---|
| Enterprise Value | $695.71 Million |
| Dividend Yield | $0.40 (-) |
| Earnings per Share | $-4.2 |
| Beta | 1.74 |
| Outstanding Shares | 25,925,600 |
Return
| Return on Equity | -6.60% |
|---|---|
| Return on Assets | -3.84% |
| Return on Invested Capital | -3.65% |
Valuation & Multiples
| P/E Ratio | -7.71 |
|---|---|
| PEG | 7.34 |
| Price to Sales | 0.56 |
| Price to Book Ratio | 0.54 |
| Enterprise Value to Revenue | 0.91 |
| Enterprise Value to EBIT | -15.31 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.64 |
| Debt to Equity | 0.57 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 10.27% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.19%▼ 510.15% |
|---|---|
| Total Invested | $42.16M▼ 95.76% |
| Investors Holding | 56▼ 204.00% |
ESG Score
No data
About Neogenomics Inc.
1,600 employeesNeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The ...
Relevant Senate Committees
This committee controls taxation, trade, and entitlement spending, crucially influencing Medicare reimbursement rates for medical services, which is a primary revenue source for NeoGenomics. Tax policy also directly impacts corporate profitability.
This committee directly allocates federal discretionary spending, which includes critical funding for healthcare research (NIH, NCI) and major healthcare programs. These decisions directly impact NeoGenomics' academic, hospital, and pharmaceutical clients' funding.
This committee directly regulates the FDA (critical for diagnostic test approvals and drug development services) and the NIH (major funder of cancer research), both of which are central to NeoGenomics' business model and client base.